Ibuprofen Lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates
This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I, n =156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II, n =60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inb...
Gespeichert in:
| Veröffentlicht in: | Indian pediatrics 2012, Vol.49 (1), p.47-49 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 49 |
|---|---|
| container_issue | 1 |
| container_start_page | 47 |
| container_title | Indian pediatrics |
| container_volume | 49 |
| creator | De Carolis, Maria Pia Bersani, I. De Rosa, G. Cota, F. Romagnoli, C. |
| description | This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I,
n
=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II,
n
=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1%
vs
50%;
P
=0.002) and surgical ligation significantly lower (8.2%
vs
23.3%;
P
=0.005) in Group I. A smaller number of neonates of Group I
vs
Group II showed oliguria and hemorrhagic disease. |
| doi_str_mv | 10.1007/s13312-012-0006-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_921143614</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>921143614</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-da4fde74baafbb2f3354534476d591cea7e534c2044756279206ec54dd70924c3</originalsourceid><addsrcrecordid>eNp9UMtOwzAQtBCIlsIHcEG-cQr4mdRHVPGoVIkLnC3Hj5IqiYsdS_TvcZTSI4eRZ72zo90B4BajB4xQ9RgxpZgUaARCZbE8A3MkKlZUnIvzzBEWRYlKPANXMe4QIpRwfAlmBAtBliWbg-26Tvvgne3h5hCbXg0Wqt7A6E2TOticus4HmOn-69CqnyZC7-A-i_sBmqSHFKEKgw2Nj5k2fZbaXHawt370jNfgwqk22pvjuwCfL88fq7di8_66Xj1tCk0ZHQqjmDO2YrVSrq6Jo5QzThmrSsMF1lZVNpeaoPzFS1IJgkqrOTOmQoIwTRfgfvLNu34nGwfZNVHbtlV5kxSlIBgzWmYsAJ6UOvgYg3VyH5pOhYPESI7xyileiUbkeOUyz9wd3VPdWXOa-MszC8gkiLnVb22QO59Cny_-x_UXhGeHEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>921143614</pqid></control><display><type>article</type><title>Ibuprofen Lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>De Carolis, Maria Pia ; Bersani, I. ; De Rosa, G. ; Cota, F. ; Romagnoli, C.</creator><creatorcontrib>De Carolis, Maria Pia ; Bersani, I. ; De Rosa, G. ; Cota, F. ; Romagnoli, C.</creatorcontrib><description>This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I,
n
=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II,
n
=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1%
vs
50%;
P
=0.002) and surgical ligation significantly lower (8.2%
vs
23.3%;
P
=0.005) in Group I. A smaller number of neonates of Group I
vs
Group II showed oliguria and hemorrhagic disease.</description><identifier>ISSN: 0019-6061</identifier><identifier>EISSN: 0974-7559</identifier><identifier>DOI: 10.1007/s13312-012-0006-8</identifier><identifier>PMID: 21992864</identifier><language>eng</language><publisher>India: Springer-Verlag</publisher><subject>Cyclooxygenase Inhibitors - therapeutic use ; Ductus Arteriosus, Patent - drug therapy ; Humans ; Ibuprofen - administration & dosage ; Ibuprofen - analogs & derivatives ; Ibuprofen - therapeutic use ; Infant, Newborn ; Infant, Premature, Diseases - drug therapy ; Lysine - administration & dosage ; Lysine - analogs & derivatives ; Lysine - therapeutic use ; Maternal and Child Health ; Medicine ; Medicine & Public Health ; Pediatric Surgery ; Pediatrics ; Research Brief ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Indian pediatrics, 2012, Vol.49 (1), p.47-49</ispartof><rights>Indian Academy of Pediatrics 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-da4fde74baafbb2f3354534476d591cea7e534c2044756279206ec54dd70924c3</citedby><cites>FETCH-LOGICAL-c343t-da4fde74baafbb2f3354534476d591cea7e534c2044756279206ec54dd70924c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13312-012-0006-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13312-012-0006-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21992864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Carolis, Maria Pia</creatorcontrib><creatorcontrib>Bersani, I.</creatorcontrib><creatorcontrib>De Rosa, G.</creatorcontrib><creatorcontrib>Cota, F.</creatorcontrib><creatorcontrib>Romagnoli, C.</creatorcontrib><title>Ibuprofen Lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates</title><title>Indian pediatrics</title><addtitle>Indian Pediatr</addtitle><addtitle>Indian Pediatr</addtitle><description>This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I,
n
=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II,
n
=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1%
vs
50%;
P
=0.002) and surgical ligation significantly lower (8.2%
vs
23.3%;
P
=0.005) in Group I. A smaller number of neonates of Group I
vs
Group II showed oliguria and hemorrhagic disease.</description><subject>Cyclooxygenase Inhibitors - therapeutic use</subject><subject>Ductus Arteriosus, Patent - drug therapy</subject><subject>Humans</subject><subject>Ibuprofen - administration & dosage</subject><subject>Ibuprofen - analogs & derivatives</subject><subject>Ibuprofen - therapeutic use</subject><subject>Infant, Newborn</subject><subject>Infant, Premature, Diseases - drug therapy</subject><subject>Lysine - administration & dosage</subject><subject>Lysine - analogs & derivatives</subject><subject>Lysine - therapeutic use</subject><subject>Maternal and Child Health</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Pediatric Surgery</subject><subject>Pediatrics</subject><subject>Research Brief</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0019-6061</issn><issn>0974-7559</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMtOwzAQtBCIlsIHcEG-cQr4mdRHVPGoVIkLnC3Hj5IqiYsdS_TvcZTSI4eRZ72zo90B4BajB4xQ9RgxpZgUaARCZbE8A3MkKlZUnIvzzBEWRYlKPANXMe4QIpRwfAlmBAtBliWbg-26Tvvgne3h5hCbXg0Wqt7A6E2TOticus4HmOn-69CqnyZC7-A-i_sBmqSHFKEKgw2Nj5k2fZbaXHawt370jNfgwqk22pvjuwCfL88fq7di8_66Xj1tCk0ZHQqjmDO2YrVSrq6Jo5QzThmrSsMF1lZVNpeaoPzFS1IJgkqrOTOmQoIwTRfgfvLNu34nGwfZNVHbtlV5kxSlIBgzWmYsAJ6UOvgYg3VyH5pOhYPESI7xyileiUbkeOUyz9wd3VPdWXOa-MszC8gkiLnVb22QO59Cny_-x_UXhGeHEw</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>De Carolis, Maria Pia</creator><creator>Bersani, I.</creator><creator>De Rosa, G.</creator><creator>Cota, F.</creator><creator>Romagnoli, C.</creator><general>Springer-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>Ibuprofen Lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates</title><author>De Carolis, Maria Pia ; Bersani, I. ; De Rosa, G. ; Cota, F. ; Romagnoli, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-da4fde74baafbb2f3354534476d591cea7e534c2044756279206ec54dd70924c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Cyclooxygenase Inhibitors - therapeutic use</topic><topic>Ductus Arteriosus, Patent - drug therapy</topic><topic>Humans</topic><topic>Ibuprofen - administration & dosage</topic><topic>Ibuprofen - analogs & derivatives</topic><topic>Ibuprofen - therapeutic use</topic><topic>Infant, Newborn</topic><topic>Infant, Premature, Diseases - drug therapy</topic><topic>Lysine - administration & dosage</topic><topic>Lysine - analogs & derivatives</topic><topic>Lysine - therapeutic use</topic><topic>Maternal and Child Health</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Pediatric Surgery</topic><topic>Pediatrics</topic><topic>Research Brief</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Carolis, Maria Pia</creatorcontrib><creatorcontrib>Bersani, I.</creatorcontrib><creatorcontrib>De Rosa, G.</creatorcontrib><creatorcontrib>Cota, F.</creatorcontrib><creatorcontrib>Romagnoli, C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Indian pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Carolis, Maria Pia</au><au>Bersani, I.</au><au>De Rosa, G.</au><au>Cota, F.</au><au>Romagnoli, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibuprofen Lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates</atitle><jtitle>Indian pediatrics</jtitle><stitle>Indian Pediatr</stitle><addtitle>Indian Pediatr</addtitle><date>2012</date><risdate>2012</risdate><volume>49</volume><issue>1</issue><spage>47</spage><epage>49</epage><pages>47-49</pages><issn>0019-6061</issn><eissn>0974-7559</eissn><abstract>This retrospective, study compared the efficacy and safety of Ibuprofen-Lysinate (Arfen, intramuscular formulation, Group I,
n
=156) used during 2000-2005 and Sodium-ibuprofen (Pedea, intravenous solution, Group II,
n
=60) used during 2006-2008, for the prophylaxis of Patent Ductus Arteriosus in inborn neonates with gestational age ≤28 weeks. Ductus closure rate after prophylaxis was significantly higher (73.1%
vs
50%;
P
=0.002) and surgical ligation significantly lower (8.2%
vs
23.3%;
P
=0.005) in Group I. A smaller number of neonates of Group I
vs
Group II showed oliguria and hemorrhagic disease.</abstract><cop>India</cop><pub>Springer-Verlag</pub><pmid>21992864</pmid><doi>10.1007/s13312-012-0006-8</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0019-6061 |
| ispartof | Indian pediatrics, 2012, Vol.49 (1), p.47-49 |
| issn | 0019-6061 0974-7559 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_921143614 |
| source | MEDLINE; SpringerNature Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Cyclooxygenase Inhibitors - therapeutic use Ductus Arteriosus, Patent - drug therapy Humans Ibuprofen - administration & dosage Ibuprofen - analogs & derivatives Ibuprofen - therapeutic use Infant, Newborn Infant, Premature, Diseases - drug therapy Lysine - administration & dosage Lysine - analogs & derivatives Lysine - therapeutic use Maternal and Child Health Medicine Medicine & Public Health Pediatric Surgery Pediatrics Research Brief Retrospective Studies Treatment Outcome |
| title | Ibuprofen Lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T19%3A45%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibuprofen%20Lysinate%20and%20sodium%20ibuprofen%20for%20prophylaxis%20of%20patent%20ductus%20arteriosus%20in%20preterm%20neonates&rft.jtitle=Indian%20pediatrics&rft.au=De%20Carolis,%20Maria%20Pia&rft.date=2012&rft.volume=49&rft.issue=1&rft.spage=47&rft.epage=49&rft.pages=47-49&rft.issn=0019-6061&rft.eissn=0974-7559&rft_id=info:doi/10.1007/s13312-012-0006-8&rft_dat=%3Cproquest_cross%3E921143614%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=921143614&rft_id=info:pmid/21992864&rfr_iscdi=true |